Back to Article:

2020 Drug Plan Trends Report: Developments, data and design

Add a comment

Have your say on this topic! Comments that are thought to be disrespectful or offensive may be removed by our Benefits Canada admins. Thanks!

* These fields are required.
Field required
Field required
Field required
Comments

Joe Farago:

Reality is, the overall market growth remains in the low single digit. The opening remarks to this piece are somewhat misleading and cherry picking facts to imply the entire health benefits space is unsustainable. To imply that private insurers should or will cover new genetic therapies, which must be administered in a public setting, is opportunistic to maintain a sky is falling message geared to selling tools being offered to manage costs. Plan sponsors would welcome some regulations or price control mechanisms being introduced on other health benefits, which are — for the most part — unregulated, except for the use of caps. Brand drugs have grown at a lower rate than dental and most other benefits for some years now.

Thursday, April 09 at 2:56 pm | Reply

Greg Hanson:

Regarding the drug pooling specific to CDIPC, can you provide the research by province in addition to what you have nationally?

Tuesday, April 14 at 2:29 pm | Reply

Join us on Twitter